Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2008 3
2009 1
2010 1
2011 2
2012 3
2013 3
2014 3
2015 5
2016 8
2017 4
2018 11
2019 9
2020 7
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

56 results
Results by year
Filters applied: . Clear all
Page 1
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt C, Zwirtes R, Sampson J, Weller M. Reardon DA, et al. Among authors: sepulveda jm. JAMA Oncol. 2020 Jul 1;6(7):1003-1010. doi: 10.1001/jamaoncol.2020.1024. JAMA Oncol. 2020. PMID: 32437507 Free PMC article. Clinical Trial.
Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
López-Valero I, Saiz-Ladera C, Torres S, Hernández-Tiedra S, García-Taboada E, Rodríguez-Fornés F, Barba M, Dávila D, Salvador-Tormo N, Guzmán M, Sepúlveda JM, Sánchez-Gómez P, Lorente M, Velasco G. López-Valero I, et al. Among authors: sepulveda jm. Biochem Pharmacol. 2018 Nov;157:266-274. doi: 10.1016/j.bcp.2018.09.007. Epub 2018 Sep 7. Biochem Pharmacol. 2018. PMID: 30195736 Free article.
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
Van Den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Chinot O, De Vos F, Whenham N, Sanghera P, Weller M, Dubbink HJ, French P, Looman J, Dey J, Krause S, Ansell P, Nuyens S, Spruyt M, Brilhante J, Coens C, Gorlia T, Golfinopoulos V. Van Den Bent M, et al. Among authors: sepulveda jm. Neuro Oncol. 2020 May 15;22(5):684-693. doi: 10.1093/neuonc/noz222. Neuro Oncol. 2020. PMID: 31747009 Free PMC article. Clinical Trial.
Dacomitinib: an investigational drug for the treatment of glioblastoma.
Sepúlveda JM, Sánchez-Gómez P, Vaz Salgado MÁ, Gargini R, Balañá C. Sepúlveda JM, et al. Expert Opin Investig Drugs. 2018 Oct;27(10):823-829. doi: 10.1080/13543784.2018.1528225. Epub 2018 Oct 5. Expert Opin Investig Drugs. 2018. PMID: 30247945 Review.
Midkine signaling maintains the self-renewal and tumorigenic capacity of glioma initiating cells.
López-Valero I, Dávila D, González-Martínez J, Salvador-Tormo N, Lorente M, Saiz-Ladera C, Torres S, Gabicagogeascoa E, Hernández-Tiedra S, García-Taboada E, Mendiburu-Eliçabe M, Rodríguez-Fornés F, Sánchez-Domínguez R, Segovia JC, Sánchez-Gómez P, Matheu A, Sepúlveda JM, Velasco G. López-Valero I, et al. Among authors: sepulveda jm. Theranostics. 2020 Apr 6;10(11):5120-5136. doi: 10.7150/thno.41450. eCollection 2020. Theranostics. 2020. PMID: 32308772 Free PMC article.
Defining EGFR amplification status for clinical trial inclusion.
French PJ, Eoli M, Sepulveda JM, de Heer I, Kros JM, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Weller M, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, van den Bent M. French PJ, et al. Among authors: sepulveda jm. Neuro Oncol. 2019 Oct 9;21(10):1263-1272. doi: 10.1093/neuonc/noz096. Neuro Oncol. 2019. PMID: 31125418 Free PMC article.
The role of pharmacogenomics in metastatic renal cell carcinoma.
Castellano D, Virizuela JA, Cruz J, Sepulveda JM, Sáez MI, Paz-Ares L. Castellano D, et al. Among authors: sepulveda jm. Cancer Metastasis Rev. 2012 Sep;31 Suppl 1:S29-32. doi: 10.1007/s10555-012-9356-x. Cancer Metastasis Rev. 2012. PMID: 22723081 Review.
The role of RANK-ligand inhibition in cancer: the story of denosumab.
Castellano D, Sepulveda JM, García-Escobar I, Rodriguez-Antolín A, Sundlöv A, Cortes-Funes H. Castellano D, et al. Among authors: sepulveda jm. Oncologist. 2011;16(2):136-45. doi: 10.1634/theoncologist.2010-0154. Epub 2011 Feb 1. Oncologist. 2011. PMID: 21285392 Free PMC article. Review.
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
van den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Chinot O, de Vos F, Whenham N, Sanghera P, Weller M, Dubbink HJ, French P, Looman J, Dey J, Krause S, Ansell P, Nuyens S, Spruyt M, Brilhante J, Coens C, Gorlia T, Golfinopoulos V. van den Bent M, et al. Among authors: sepulveda jm. Neuro Oncol. 2020 Jul 1:noaa115. doi: 10.1093/neuonc/noaa115. Online ahead of print. Neuro Oncol. 2020. PMID: 32609812 No abstract available.
56 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page